drugset
drugset / Trial / NCT07808060

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

NCT07808060 ↗

Phase 1 Recruiting 34 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Research Unit (CRU), each lasting between 6 - 8 nights.

Timeline

Start
2026-09-15
Primary completion
2027-06
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Eloralintide Protein / enzyme biologic — Subcutaneous
Subject Levonorgestrel Small molecule — Oral
Subject ethinyl estradiol Small molecule — Oral

Indications

obesity disorder